Validation of an Algorithm to Ascertain Late Breast Cancer Recurrence Using Danish Medical Registries

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Hovaldt HB, Suppli NP, Olsen MH, et al. Who are the cancer survivors? A nationwide study in Denmark, 1943-2010. Br J Cancer. 2015;112(9):1549–1553. doi:10.1038/bjc.2015.6825719832
   PubMed Web of Science ®Google Scholar
• Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet (London, England). 2000;355(9217):1822. doi:10.1016/S0140-6736(00)02277-7
   PubMed Web of Science ®Google Scholar
• Cianfrocca M. Overcoming recurrence risk: extended adjuvant endocrine therapy. Clin Breast Cancer. 2008;8(6):493–500. doi:10.3816/CBC.2008.n.05919073503
   PubMed Web of Science ®Google Scholar
• Park J-H, Anderson WF, Gail MH. Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status. J Clin Oncol. 2015;33(26):2870–2876. doi:10.1200/JCO.2014.59.919126195709
   PubMed Web of Science ®Google Scholar
• Tryggvadóttir L, Gislum M, Bray F, et al. Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010;49(5):624–631. doi:10.3109/0284186090357532320429724
   PubMed Web of Science ®Google Scholar
• Richman J, Dowsett M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat Rev Clin Oncol. 2019;16(5):296–311. doi:10.1038/s41571-018-0145-530563978
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi:10.1056/NEJMoa170183029117498
   PubMed Web of Science ®Google Scholar
• Kostev K, Kalder M. 20-year risk of breast cancer recurrence. Breast Cancer Res Treat. 2018;168(3):765–766. doi:10.1007/s10549-017-4636-329299725
   PubMed Web of Science ®Google Scholar
• Møller S, Jensen M-B, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47(4):506–524. doi:10.1080/0284186080205925918465317
   PubMed Web of Science ®Google Scholar
• Lash TL, Riis AH, Ostenfeld EB, Erichsen R, Vyberg M, Thorlacius-Ussing O. A validated algorithm to ascertain colorectal cancer recurrence using registry resources in Denmark. Int J Cancer. 2015;136(9):2210–2215. doi:10.1002/ijc.2926725307704
   PubMed Web of Science ®Google Scholar
• Rasmussen LA, Jensen H, Virgilsen LF, Jensen JB, Vedsted P. A validated algorithm to identify recurrence of bladder cancer: a register-based study in Denmark. Clin Epidemiol. 2018;10:1755–1763. doi:10.2147/CLEP.S17730530538579
   PubMed Web of Science ®Google Scholar
• Aagaard Rasmussen L, Jensen H, Flytkjær Virgilsen L, Jellesmark Thorsen LB, Vrou Offersen B, Vedsted P. A validated algorithm for register-based identification of patients with recurrence of breast cancer-based on Danish Breast Cancer Group (DBCG) data. Cancer Epidemiol. 2019;59:129–134. doi:10.1016/j.canep.2019.01.01630743224
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Kjærsgaard A, Nørgaard M, et al. Clinical outcomes of female breast cancer according to BRCA mutation status. Cancer Epidemiol. 2017;49:128–137. doi:10.1016/j.canep.2017.05.01628601786
   PubMed Web of Science ®Google Scholar
• Henriksen DP, Rasmussen L, Hansen MR, Hallas J, Pottegård A. Comparison of the five danish regions regarding demographic characteristics, healthcare utilization, and medication use – a descriptive cross-sectional study. PLoS One. 2015;10(10):e0140197. doi:10.1371/journal.pone.014019726439627
   PubMed Web of Science ®Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-324965263
   PubMed Web of Science ®Google Scholar
• Jensen AR, Storm HH, Møller S, Overgaard J. Validity and representativity in the Danish Breast Cancer Cooperative Group – a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol. 2003;42(3):179–185. doi:10.1080/0284186031000073712852693
   PubMed Web of Science ®Google Scholar
• Kaufmann N. Pakkeforløb for brystkræft. 2018.
   Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health. 2011;39(7_suppl):30–33. doi:10.1177/140349481140148221775347
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi:10.2147/CLEP.S9112526604824
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish national pathology registry and data bank. Clin Epidemiol. 2010;2:51–56. doi:10.2147/CLEP.S990820865103
   PubMedGoogle Scholar
• Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish cancer registry – history, content, quality and use. Dan Med Bull. 1997;44(5):535–539.9408738
   PubMed Web of Science ®Google Scholar
• Rasmussen CB, Kjær SK, Ejlertsen B, et al. Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. Int J Epidemiol. 2014;43(6):1855–1864. doi:10.1093/ije/dyu20225326461
   PubMed Web of Science ®Google Scholar
• Han HH, Lee SH, Kim BG, Lee JH, Kang S, Cho NH. Estrogen receptor status predicts late-onset skeletal recurrence in breast cancer patients. Medicine (Baltimore). 2016;95(8):e2909. doi:10.1097/MD.000000000000290926937933
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10):2738–2746. doi:10.1200/JCO.1996.14.10.27388874335
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or iCombination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet (London, England). 2005;365(9453):60–62. doi:10.1016/S0140-6736(04)17666-6
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255–268. doi:10.2307/25320512720055
   PubMed Web of Science ®Google Scholar
• Ritzwoller DP, Hassett MJ, Uno H, et al. Development, validation, and dissemination of a breast cancer recurrence detection and timing informatics algorithm. J Natl Cancer Inst. 2018;110(3):273–281. doi:10.1093/jnci/djx20029873757
   PubMedGoogle Scholar
• Chubak J, Onega T, Zhu W, Buist DSM, Hubbard RA. An electronic health record-based algorithm to ascertain the date of second breast cancer events. Med Care. 2017;55(12):e81–e87. doi:10.1097/MLR.000000000000035229135770
   PubMed Web of Science ®Google Scholar
• Chubak J, Yu O, Pocobelli G, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. 2012;104(12):931–940. doi:10.1093/jnci/djs23322547340
   PubMedGoogle Scholar
• Kroenke CH, Chubak J, Johnson L, Castillo A, Weltzien E, Caan BJ. Enhancing breast cancer recurrence algorithms through selective use of medical record data. J Natl Cancer Inst. 2016;108(3). doi:10.1093/jnci/djv336
   Google Scholar
• Lamont EB, Herndon IIJE, Weeks JC, et al. Measuring disease-free survival and cancer relapse using medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006;98(18):1335–1338. doi:10.1093/jnci/djj36316985253
   PubMedGoogle Scholar
• Warren JL, Mariotto A, Melbert D, et al. Sensitivity of medicare claims to identify cancer recurrence in elderly colorectal and breast cancer patients. Med Care. 2016;54(8):e47–e54. doi:10.1097/MLR.000000000000005824374419
   PubMed Web of Science ®Google Scholar
• Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using two large contemporary cohorts. Med Care. 2014;52(10):e65–e73. doi:10.1097/MLR.0b013e318277eb6f23222531
   PubMed Web of Science ®Google Scholar
• Chawla N, Yabroff KR, Mariotto A, McNeel TS, Schrag D, Warren JL. Limited validity of diagnosis codes in medicare claims for identifying cancer metastases and inferring stage. Ann Epidemiol. 2014;24(9):666–672, 672.e1-2. doi:10.1016/j.annepidem.2014.06.099
   Web of Science ®Google Scholar